11 – 20 of 59
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma
(
- Contribution to journal › Article
- 2019
-
Mark
Integrated epigenomic and transcriptomic analysis reveals TP63 as a novel player in clinically aggressive chronic lymphocytic leukemia
(
- Contribution to journal › Article
-
Mark
Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide
(
- Contribution to journal › Article
- 2018
-
Mark
Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity
(
- Contribution to journal › Article
-
Mark
A platform for phenotypic discovery of therapeutic antibodies and targets applied on Chronic Lymphocytic Leukemia
(
- Contribution to journal › Article
- 2017
-
Mark
Frequency and clinical implications of SOX11 expression in Burkitt lymphoma
(
- Contribution to journal › Letter
-
Mark
Genome-Wide DNA Methylation Profiling of Chronic Lymphocytic Leukemia Subsets Carrying Stereotyped B Cell Receptors
(
- Contribution to journal › Published meeting abstract
-
Mark
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy
(
- Contribution to journal › Article
-
Mark
Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma.
(
- Contribution to journal › Article
- 2016
-
Mark
SOX11 and HIG-2 are cross-regulated and affect growth in mantle cell lymphoma.
2016) In Leukemia & Lymphoma(
- Contribution to journal › Article